# Rocket Pharmaceuticals, Inc.: overview RCKT · Nasdaq · CIK 1281895 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rckt.md) · [Financials](/companies/rckt/financials.md) · [Filings](/companies/rckt/filings.md) · [Insiders](/companies/rckt/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-342348.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-342348). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-25-269474.md) | [0.0 d](/filings/0001193125-26-076551.md) | [0.0](/filings/0001193125-26-211873.md) | [0.0](/filings/0001193125-26-342348.md) | [0.0](/filings/0001193125-25-269474.md) | [0.0 d](/filings/0001193125-26-076551.md) | [0.0](/filings/0001193125-26-211873.md) | [0.0](/filings/0001193125-26-342348.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.71)](/filings/0001193125-25-269474.md) | not reported | [(0.56)](/filings/0001193125-26-211873.md) | [(0.62)](/filings/0001193125-26-342348.md) | [(0.45)](/filings/0001193125-25-269474.md) | not reported | [(0.42)](/filings/0001193125-26-211873.md) | [1.08](/filings/0001193125-26-342348.md) | | Free cash flow | $m | [(53.7) d](/filings/0001193125-25-269474.md) | [(47.3) d](/filings/0001193125-26-076551.md) | [(56.2)](/filings/0001193125-26-211873.md) | [(49.0) d](/filings/0001193125-26-342348.md) | [(50.5) d](/filings/0001193125-25-269474.md) | [(34.9) d](/filings/0001193125-26-076551.md) | [(45.5)](/filings/0001193125-26-211873.md) | [(39.6) d](/filings/0001193125-26-342348.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0000950170-24-021096.md) | [0.0](/filings/0000950170-25-029002.md) | [0.0](/filings/0000950170-25-029002.md) | [0.0](/filings/0001193125-26-076551.md) | [0.0](/filings/0001193125-26-076551.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.67)](/filings/0000950170-24-021096.md) | [(3.26)](/filings/0000950170-25-029002.md) | [(2.92)](/filings/0000950170-25-029002.md) | [(2.73)](/filings/0001193125-26-076551.md) | [(2.01)](/filings/0001193125-26-076551.md) | | Free cash flow | $m | [(129)](/filings/0000950170-24-021096.md) | [(187)](/filings/0000950170-25-029002.md) | [(211)](/filings/0000950170-25-029002.md) | [(216)](/filings/0001193125-26-076551.md) | [(190)](/filings/0001193125-26-076551.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rckt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $60.5m | 17,687,772 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $33.9m | 9,923,962 | | Added +2,089,167 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $19.9m | 5,810,033 | | Added +1,119,818 | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $16.6m | 4,865,551 | | Reduced −242,157 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $13.8m | 4,029,262 | | Added +990,547 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $13.7m | 4,000,344 | | Added +882,220 | | [Newtyn Management, LLC](/funds/1569241.md) | 2026-06-30 | $13.7m | 4,000,000 | | Added +834,100 | | [MAVERICK CAPITAL LTD](/funds/934639.md) | 2026-06-30 | $13.4m | 3,923,963 | | Added +356,591 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.9m | 3,784,387 | | Added +8,651 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $11.6m | 3,386,162 | | Added +316,232 | ## Recent filings [All 955 filings](/companies/rckt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 17:15 ET | [8-K](/filings/0001140361-26-038818.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-038818 | | 2026-09-15 | 07:06 ET | [8-K](/filings/0001140361-26-036563.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-036563 | | 2026-08-27 | 16:06 ET | [8-K](/filings/0001140361-26-034689.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-034689 | | 2026-08-10 | 16:17 ET | [8-K](/filings/0001140361-26-032028.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032028 | | 2026-08-10 | 16:05 ET | [10-Q](/filings/0001193125-26-342348.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342348 | | 2026-08-03 | 07:41 ET | [8-K](/filings/0001140361-26-030568.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-030568 | | 2026-06-30 | 17:16 ET | [8-K](/filings/0001140361-26-026982.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-026982 | | 2026-06-12 | 07:10 ET | [8-K](/filings/0001140361-26-024997.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-024997 | | 2026-05-21 | 06:02 ET | [8-K](/filings/0001140361-26-022311.md) | 5.07 Shareholder vote results | 0001140361-26-022311 | | 2026-05-07 | 16:45 ET | [8-K](/filings/0001140361-26-019573.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-019573 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076551.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a1f009fe-88d2-4913-bfc6-e659084e8a09) ## About the filer - CIK: 1281895 - Tickers: RCKT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 13:58 ET. No prices; not investment advice.